Norwegian School of Sport Sciences
Oslo, 0863, Norway
NCT Number: NCT03326648
The purpose of this study is to investigate mechanisms underlying the reduction in muscle quality (the ratio between muscle strength and muscle size) with aging, and to investigate how these factors are affected by strength training and protein supplementation. It is already established that muscle quality defined as the ratio between the strength and the size of a muscle is improved with strength training, even in frail elderly individuals. However, the relative contribution of factors such as activation level, fat infiltration, muscle architecture and single fiber function is unknown. The main focus of this study is to investigate the relationship between muscle quality and muscle protein breakdown, as insufficient degradation of proteins is hypothesized to negatively affect muscle quality.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Oslo, 0863, Norway
Aging is associated with impaired skeletal muscle function. This is evident not only by a reduced capacity to generate force and power at the whole muscle level, but also by a decline in individual muscle fiber contraction velocity and force generation. Combined with muscle atrophy, these changes lead to reduced muscle strength and quality and loss off physical function with age. Clinically, muscle quality may be a better indicator of overall functional capacity than absolute muscle strength. Thus, identifying the mechanisms underlying the age-related loss of muscle quality is of high relevance for the prevention of functional impairment with aging. The explanation for the loss of muscle quality with aging seems to be multifactorial, with alterations in voluntary muscle activation, muscle architecture, fat infiltration and impaired contractile properties of single muscle fibers being likely contributors. Single fiber specific force seems to be related to myosin heavy chain (MHC) content, which is thought to reflect the number of available cross-bridges. The reduction of single fiber specific force with aging may thus be a consequence of reduced synthesis of MHC and/or increased concentration of non-contractile tissue (e.g. intramyocellular lipids).
Some studies in mice also indicate attenuated activity in some of the pathways responsible for degradation of muscle proteins with aging (especially autophagy). As a result, damaged proteins and organelles are not removed as effectively as they should, which could ultimately compromise the muscle's ability to produce force. In addition, reduced efficiency of mitophagy and lipophagy (two specific forms of autophagy), may indirectly affect single fiber specific force, through oxidative damage by reactive oxygen species (ROS) and increased levels of intramyocellular lipids, respectively. Although animal studies indicate attenuated autophagic function, exercise seems to restore the activity in this pathway. Whether this also is the case in humans is unknown. Thus, the purpose of this study is to investigate how the different factors contributing to reduced muscle quality in frail elderly individuals, with emphasis on the relationship between muscle quality and autophagy, may be counteracted by a specific strength training program targeting muscle quality and muscle mass.
In this randomized controlled trial the investigators will aim to recruit frail elderly individuals, as muscle quality is shown to be low in this population. As a consequence, the potential for improved muscle quality is expected to be large. Subjects will be randomized to two groups; one group performing strength training twice a week for 10 weeks in addition to receiving daily protein supplementation. The other group will only receive the protein supplement. Several tests will be performed before and after the intervention period, including a test day where a biopsy is obtained both at rest, and 2.5 hours following strength training + protein supplementation or protein supplementation only. This will provide information about the regulation of muscle protein breakdown in a resting state, following protein intake and following strength training in combination with protein intake. As this will be done both before and after the training period, it will also provide information on how long-term strength training affects the activity in these systems.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Heavy load strength training performed twice a week for 10 weeks.
Other names: Resistance training
Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
Time frame: Change from baseline at 10 weeks
A measure of muscle quality at the single fiber level. Biopsies obtained from m. Vastus Lateralis
Time frame: Change from baseline at 10 weeks
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Time frame: Change from baseline at 10 weeks
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Time frame: Change from baseline at 10 weeks
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
Time frame: Change from baseline at 10 weeks
Maximal isometric and dynamic muscle strength of m. quadriceps
Time frame: Change from baseline at 10 weeks
Cross-sectional area of m. quadriceps measured by a Computed Tomography scan
Time frame: Change from baseline at 10 weeks
Fat infiltration of m. quadriceps measured by a Computed Tomography scan
Time frame: Change from baseline at 10 weeks
Voluntary activation level during a maximal isometric knee extension using the interpolated twitch technique
Time frame: Measured over the last 14 days of the intervention period
Measurement of fractional breakdown rate by the use of orally provided Deuterium Oxide, biopsies and blood samples
Time frame: Change from baseline at 10 weeks
Measured by ultrasound
Time frame: Change from baseline at 10 weeks
Time (sec) to stand up from a chair five times
Time frame: Change from baseline at 10 weeks
Time (sec) to walk 6 meters at habitual gait velocity
Time frame: Change from baseline at 10 weeks
Time (sec) to walk 6 meters as fast as possible
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Change from baseline at 10 weeks
Fasted
Time frame: Change from baseline at 10 weeks
Fasted
Time frame: Change from baseline at 10 weeks
Fasted
Time frame: Change from baseline at 10 weeks
Fasted
Time frame: Change from baseline at 10 weeks
Fasted
Time frame: Change from baseline at 10 weeks
Fasted
Time frame: Change from baseline at 10 weeks
Fasted
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
Biopsies from m. Vastus Lateralis analyzed by western blot
Time frame: Change from baseline at 10 weeks
Oil-Red-O staining of muscle sections. Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time frame: Change from baseline at 10 weeks
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time frame: Change from baseline at 10 weeks
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time frame: Change from baseline at 10 weeks
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time frame: Change from baseline at 10 weeks
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
Time frame: Change from baseline at 10 weeks
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Time frame: Change from baseline at 10 weeks
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Time frame: Change from baseline at 10 weeks
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Time frame: Change from baseline at 10 weeks
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
Truls Raastad
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07580144
Atrophy, Frailty
Konya, Turkey (Türkiye)
View Trial DetailsNCT07660653
Atrophy, Frailty
Jiaozuo, Henan, China
View Trial DetailsNCT07049809
Adherence, Atrophy
Barcelona, Spain
View Trial DetailsNCT05294757
Atrophy, Behavior
Albacete, Castille-La Mancha, Spain
View Trial Details